Skip to main content
OpenTrials
Completed

NCT Number: NCT07146191

RE104 Radiolabeled Mass Balance (hAME) Study

The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of [14C]-RE104.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

PPD Inc.

Austin, Texas, 78744, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 18 and 55 years of age (inclusive), and a body mass index of 18-34 kg/m2.
  • Willing to take a drug with psychoactive properties
  • If female and of childbearing potential, agrees to use an acceptable method of birth control and is not planning to become pregnant before, during or within 90 days after the last dose of the study drug.
  • If male, must agree to use condom with spermicide during and up to 90 days after discharge."
  • Must agree to refrain from sperm or egg donation until 120 days post discharge.
  • Able to understand and adhere to study schedule and requirements and willing to sign an ICF
  • In good general health as determined by medical history, clinical laboratory test results, vital sign measurements, 12-lead ECG results, and physical examination findings at screening
  • Agrees to not participate in other research studies involving investigational medication or medical devices for the duration of the study

Exclusion criteria

  • Active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder.
  • Medical condition or other concomitant condition or history rendering unsuitability for the study
  • Has used or intends to use prohibited medications
  • Has a known sensitivity or intolerance to hallucinogenic or psychedelic substances, or potential rescue medications
  • Has participated in another clinical study within 30 days and/or with a [14C] labeled study drug within 1 year prior to enrolling.
  • Is pregnant or has a female partner who is pregnant

Treatment and study plan

2-[14C]-RE104 for Injection

Drug

Single, subcutaneous dose of 2-[14C]-RE104 for Injection

Primary outcomes

  1. Total excreted radioactivity (Ae)

    Time frame: Through 168 hours postdose

  2. Cumulative recovery of total excreted radioactivity (CUM Ae)

    Time frame: Through 168 hours postdose

  3. Area under the concentration-time curve (AUC) for RE104 and 4-OH-DiPT

    Time frame: Through 168 hours postdose

  4. Maximum observed concentration (Cmax) for RE104 and 4-OH-DiPT

    Time frame: Through 168 hours postdose

  5. Time to reach Cmax (Tmax) for RE104 and 4-OH-DiPT

    Time frame: Through 168 hours postdose

  6. Terminal half-life (t1/2) of RE104 and 4-OH-DiPT

    Time frame: Through 168 hours postdose

  7. Apparent terminal elimination half-life (λz) for RE104 and 4-OH-DiPT

    Time frame: Through 168 hours postdose

  8. Mean residence time (MRT)

    Time frame: Through 168 hours postdose

  9. Apparent total body clearance (CL/F) for RE104

    Time frame: Through 168 hours postdose

  10. Apparent volume of distribution during the terminal phase (Vz/F) for RE104

    Time frame: Through 168 hours postdose

  11. Total metabolite profiling with description of relevant PK parameters and structural identification of major metabolites present in all matrices

    Time frame: Through 168 hours postdose

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness

    Time frame: From dosing (Day 0) through study completion (Day 7)

    A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.

Sponsors and collaborators

Lead sponsor

Reunion Neuroscience Inc

Industry

Registry information

Official study title

A Phase 1, Open-label, Single Period Study to Evaluate the Absorption, Metabolism, and Excretion of a Single Microdose of [14C]-RE104 in Healthy Participants

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 28, 2025
Registry last updated
Nov 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.